[HUGE RENAL ANGIOMYOLIPOMA (AML) IN TUBEROUS SCLEROSIS COMPLEX (TSC) WHICH IS CONTROLED BY EVEROLIMUS: A CASE REPORT]

Nihon Hinyokika Gakkai Zasshi. 2016;107(1):54-58. doi: 10.5980/jpnjurol.107.54.
[Article in Japanese]

Abstract

We report a 43-year-old TSC man with repeated hemorrhage of bilateral renal AML. He was diagnosed with TSC based on the findings of facial angiofibroma, mental retardation and epilepsy in childhood. In 2011, he experienced three times in AML-associated hemorrhage from the left kidney and received selective transarterial embolotherapy (TAE). In 2013, he also experienced AML-associated hemorrhage from the right kidney and received selective TAE. To control his AML, treatments with Everolimus was started and well tolerated. So far, his renal AML remarkably shrunk without retroperitoneal hemorrhage for 24 months, while he had some episode of side effect.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angiomyolipoma / drug therapy*
  • Angiomyolipoma / etiology
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Brain / diagnostic imaging
  • Everolimus / administration & dosage*
  • Everolimus / adverse effects
  • Hemorrhage / drug therapy
  • Hemorrhage / etiology
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / etiology
  • Leukopenia / chemically induced
  • Male
  • Recurrence
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Tuberous Sclerosis / complications*
  • Tuberous Sclerosis / diagnostic imaging
  • Tuberous Sclerosis / pathology

Substances

  • Antineoplastic Agents
  • Everolimus